Following Eisai/Biogen's Lecanemab (trade name: Leqembi), the second new Alzheimer's disease drug approved for marketing in China has been launched by Eli Lilly.

On December 18, Eli Lilly announced that the world's second new Alzheimer's disease (AD) drug donanemab injection (trade name: Kisunla) was approved for marketing by China's National Medical Products Administration for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease in adults.

Regarding the question of whether the price of the world's second new Alzheimer's disease drug will drop, a medical expert said that this usually depends on a variety of factors, including market demand, drug efficacy, production costs, and market competition.

With the development and marketing of more similar drugs, market competition may intensify, prompting prices to fall.

However, this also needs to take into account the high cost of drug research and development and the company's profit needs.